Cabaletta Bio®

Corporate Presentation

MAY 2022

© 2022 Cabaletta Bio. All rights reserved.

Disclaimer

The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the presentation (collectively, the "Presentation") has been prepared by Cabaletta Bio, Inc. ("we," "us," "our," "Cabaletta" or the "Company") and is made for informational purposes only. This Presentation does not purport to be a prospectus, to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this Presentation unless stated otherwise, and this Presentation shall not under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof. This Presentation may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations, and financial conditions, and include, but are not limited to, express or implied statements regarding our current beliefs, expectations and assumptions regarding: our business, future plans and strategies for our CAAR T technology and CABATM platform; the progress and results of our DesCAARTesTM Phase 1 trial, including the significance and impact around the clinical and translational data updates from cohorts A1 through A4 of our DesCAARTesTM Phase 1 trial; the expected timing and significance of the announcement of 28-day safety for cohort A5 and clinical and translational data for cohort A4 in mid-2022; the therapeutic potential and clinical benefits of our product candidates; the expectation that Cabaletta Bio may improve outcomes for patients suffering from mucosal pemphigus vulgaris; our ability to continue progressing in cohort A5, including the planned addition of an enhanced manufacturing process in cohort A5e; our ability to escalate dosing as high as 10 to 15 billion cells in cohort A6m or otherwise; our ability to advance dose escalation in the DesCAARTesTM Phase 1 trial at the current dose ranges for the current cohorts and any projected potential dose ranges for future cohorts, and to optimize our targeted cell therapy; our ability to evaluate, and the potential significance of, the relationship between DSG3-CAART persistence and potential clinical responses in patients with mPV; our ability to safely retreat additional patients and whether we will continue to observe a lack of immune-mediated clearance of DSG3-CAART cells after retreatment and repeat dosing of patients; our ability to successfully complete our preclinical and clinical studies for our product candidates, including our ongoing Phase 1 DesCAARTesTM trial, our planned clinical trial of MuSK-CAART, including our ability to enroll the requisite number of patients, dose each dosing cohort in the intended manner, and progress the trial; the ability of MuSK-CAART to target B cells that differentiate into antibody secreting cells, which produce autoantibodies against muscle-specific kinase; our ability to obtain and maintain regulatory approval of our product candidates, including our expectations regarding the intended incentives conferred by and ability to retain Orphan Drug Designation and Fast Track Designation for DSG3-CAART for the treatment of pemphigus vulgaris and Fast Track Designation for MuSK-CAART to improve activities of daily living and muscle strength in patients with MuSK antibody-positive myasthenia gravis; the further expansion and development of our modular CABATM platform across a range of autoimmune diseases; our ability to contract with third-party suppliers and manufacturers, implement an enhanced manufacturing process and further develop our internal manufacturing strategy, capabilities and facilities; our potential commercial opportunities, including value and addressable market, for our product candidates; our expectations regarding our use of capital and other financial results; and our ability to fund operations through the third guarter of 2023. Words such as, but not limited to, "look forward to," "estimate," "estimate," "intend," "plan," "would," "should" and "could." and similar expressions or words, identify forward-looking statements.

Various risks, uncertainties and assumptions could cause actual results to differ materially from those anticipated or implied in our forward-looking statements. Such risks and uncertainties include, but are not limited to, risks related to the success, cost, and timing of our product candidate development activities and preclinical studies and clinical trials, risks related to our ability to demonstrate sufficient evidence of safety, efficacy and tolerability in our preclinical and clinical trials of DSG3-CAART and MuSK-CAART, the risk that signs of biologic activity or persistence may not inform long-term results, the risk that persistence observed with effective CART-19 oncology studies in combination with lymphodepletion is not indicative of, or applicable to, clinical responses in patients with mPV; risks related to clinical trial site activation or enrollment rates that are lower than expected, our ability to protect and maintain our intellectual property position, risks related to our relationship with third parties, uncertainties related to regulatory agencies' evaluation of regulatory filings and other information related to our product candidates, our ability to retain and recognize the intended incentives conferred by any Orphan Drug Designation and Fast Track Designations, the risk that any one or more of our product candidates will not be successfully developed and commercialized, the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies, the impact of COVID-19 on the timing. progress, interpretability of data, and results of ongoing or planned clinical trials and risks relating to as a result of extraordinary events or circumstances such as the COVID-19 pandemic, and any business interruptions to our operations or to those of our clinical sites, manufacturers, suppliers, or other vendors resulting from the COVID-19 pandemic or similar public health crisis. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ materially from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in our other filings with the Securities and Exchange Commission. Certain information contained in this Presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company's own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this Presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. The Company is the owner of various trademarks, trade names and service marks. Certain other trademarks, trade names and service marks appearing in this Presentation are the property of third parties. Solely for convenience, the trademarks and trade names in this Presentation are referred to without the ® and TM symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. 2



Develop and launch the first curative targeted cellular therapies for patients with autoimmune diseases

Cabaletta[®] overview

> Developing highly specific CAAR T products to treat B cell-mediated autoimmune diseases

DesCAARTes[™] trial in patients with mucosal pemphigus vulgaris (mPV) ongoing

- Favorable safety profile for DSG3-CAART demonstrated in cohorts A1 through A4 at doses up to 2.5 billion cells
 - No CRS, ICANS, dose-limiting toxicities or related SAEs observed in any patient in cohorts A1 to A4
- Dose-dependent increase in DSG3-CAART persistence observed in cohorts A1 to A4, as presented at 25th Annual ASGCT Conference
 - Cohort A4 persistence approached the lower end of the range seen with anti-CD19 CART with lymphodepletion in oncology^{1,2,3}
- Cohort A5 dosing up to 7.5 billion cells ongoing with multiple additional cohorts possible to enhance in vivo DSG3-CAART exposure

S MusCAARTes[™] trial in patients with MuSK myasthenia gravis on track to initiate in 2022

Cell therapy pipeline⁴ targeting diseases that affect over 80,000 U.S. patients


S Cash runway through 3Q23 with \$109.2M in cash and investments at the end of 1Q22

- CRS Cytokine release syndrome; ICANS Immune effector cell-associated neurotoxicity syndrome; SAE Serious adverse event
- 1. Mueller, Karen Thudium, et al. "Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia." Blood, The Journal of the American Society of Hematology 130.21 (2017): 2317-2325.
- 2. Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019;380(1):45-56. doi:10.1056/NEJMoa1804980
- 3. The range of persistence observed with anti-CD19 CART therapy in oncology has not been confirmed to be necessary or sufficient for clinical responses in patients with mPV.
- 4. Includes five disclosed product candidates and two undisclosed pipeline disease targets in our pipeline.




Our scientific platform leverages clinically validated CAR T technology

CAAR T product candidates are designed for selective and specific elimination of the pathogenic B cells



Cabaletta: Advancing targeted cell therapy to autoimmunity


Foundational CAR T technology clinically validated in treating B cell-mediated cancers



Modular platform with "plug-and-play" architecture

CABA[™] platform designed to enable a portfolio of programs targeting B cell-mediated diseases

Swapping the extracellular domain, or autoantigen, creates new product candidates



Clinically validated engineered T cell platform is the foundational technology

Pipeline¹ includes multiple disease targets where cure is possible

Therapeutic Area	Indication	Program	Discovery ²	Preclinical	Phase 1	Phase 2/3
	Mucosal Pemphigus Vulgaris	DSG3-CAART				
Dermatology	Mucocutaneous Pemphigus Vulgaris	DSG3/1-CAART				
Neurology	MuSK Myasthenia Gravis	MuSK-CAART				
Rya Nephrology	PLA2R Membranous Nephropathy	PLA2R-CAART				
Hematology	Hemophilia A w/ FVIII Alloantibodies	FVIII-CAART				

Current pipeline includes 7 programs targeting diseases affecting >80,000 patients in the U.S.

1. Two additional undisclosed disease targets currently in discovery stage are not shown in our pipeline portfolio. 2. In our discovery stage, we perform epitope mapping and optimize CAAR construct and design.



DSG3-CAART for patients with mucosal pemphigus vulgaris

Overview of pemphigus vulgaris

Current treatments require broad immunosuppression associated with safety risks and transient efficacy

	Mucosal PV ¹ 25% of U.S. pemphigus vulgaris	Mucocutaneous PV ² 75% of U.S. pemphigus vulgaris	Current Treatment Landscape Broad immunosuppression ^{3,6} • Modestly effective • Poorly tolerated	
		MAR CAR ENT	Rituximab plus steroids (~3,500 mg/yr	
			 Response: ~40% of patients achieved period with no lesions or medicines du 	
Associated Antibody	Anti-DSG3	Anti-DSG3 + Anti-DSG1	 22% annual serious adverse event (S. 4-9%^{3,4,5} annual risk of severe inf 	
Clinical Signs	Painful blisters of the mucous membranes (mouth, nose, larynx, esophagus, eyes, genitalia, rectum)	Blisters on orifices and skin	 Real world data indicate: <i>Transient</i> remission ~ 70% CRO 	
US Disease Prevalence	3,250 to 4,750	9,750 to 14,250	 ~30% relapse in 1 year⁶ >50% relapse within 2 years 	

CROT = 8+ weeks without lesions while off systemic therapy

- 1. Image credit: D@nderm.
- 2. http://www.vgrd.org/archive/cases/2004/pv/DSCN4996%20copy.JPG


Rituximab plus steroids (~3,500 mg/yr)⁴

- Response: ~40% of patients achieved a 16-week period with no lesions or medicines during 1 yr^{4,5}
- 22% annual serious adverse event (SAE) rate⁴
 - 4-9%^{3,4,5} annual risk of severe infection in PV
- Real world data indicate:
 - Transient remission ~ 70% CROT⁶:
 - ~30% relapse in 1 year⁶
 - >50% relapse within 2 years⁶
 - ~30% never achieve CROT⁶
 - ~1.9% lifetime risk of fatal infection⁷
- 3. Joly, Pascal, et al. "First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial." The Lancet 389.10083 (2017): 2031-2040.
- 4. Werth, Victoria P., et al. "Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris." New England Journal of Medicine (2021).
- Rituximab label, 08/2020 revision.
- 6. Kushner, Carolyn J., et al. "Factors Associated With Complete Remission After Rituximab Therapy for Pemphigus." JAMA dermatology (2019).
- 7. Tony, Hans-Peter, et al. "Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)." Arthritis research & therapy 13.3 (2011): 1-14.



DSG3-CAART is designed to bind all known pathogenic autoantibodies

Inclusion of all disease-relevant epitopes enables a 'one-size-fits-all' approach for patients with mPV



Cabaletta Bio[®]

11

1. Ohyama, Bungo, et al. "Epitope spreading is rarely found in pemphigus vulgaris by large-scale longitudinal study using desmoglein 2–based swapped molecules." Journal of investigative dermatology 132.4 (2012): 1158-1168.

2. Antibodies that target the specific extracellular domain are shown below each extracellular domain.

3. Amagai, Masayuki, et al. "Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic." The Journal of clinical investigation 90.3 (1992): 919-926.

DesCAARTes[™] Phase 1 study of DSG3-CAART¹

Trial in patients with mPV evaluating up to 750x dose range (20M up to 10-15B cells)

Orphan Drug Designation Designation

Cabaletta Bio[®]

12


Screening	Apheresis	DSG3-CAAR INFUSION	т		
•			TREATMENT & F	OLLOW-UP PERIOD	Next Patient
Major Inclusion Criteria	2 T cells lentivirally transduced with	3 DSG3 CAAR T cell expansion	Part A Cohorts ^{2,3}	Subjects	Dose*
Age: ≥18, confirmed diagnosis	DSG3 CAAR		A1	3 (+3)	20M
Inadequately managed by standard		0.0	A2	3 (+3)	100M
immunosuppressive therapies		000	A3	3 (+3)	500M
Confirmed diagnosis Active disease	1 White blood	4 DSG3 CAAR T	A4	3 (+3)	2.5B
Anti-DSG3 antibody positive			A5	3 (+3)	5.0B to 7.5B
Major Exclusion Criteria	cells (including	cells are infused into the patient	A5e⁴	3 (+3)	5.0B to 7.5B
	T cells) are collected	into the patient	A6 <i>m</i> ⁵	3 (+3)	10B to 15B
Recent rituximab Prednisone > 0.25 mg/kg/day Other autoimmune disorder requiring immunosuppressive therapies Recent investigational treatment ALC < 1,000 at screening Phase 1 Trial (NCT04422912).		pressants are stopped; ow dose prior to infusion	Primary objective: Determine the maximum dose of DSG3-CAART Primary endpoint: Adverse events, including limiting toxicities (DLTs), DSG3-CAART within 3 m infusion	tolerated • Manu • DSG3 • Anti-E • Conce g dose- related to	dary objectives: facturing success rate B-CAART persistence DSG3 antibody titer chang omitant medication chang al disease activity score c

- 3. Cohort progression following A5 (e.g. A5e or A6m) is to be prioritized according to emerging data and discussions with the FDA, as applicable.
- 4. Cohort A5e reflects an enhanced manufacturing process designed to amplify the already present cell subtypes in the product in order to potentially improve product potency and trafficking.
- 5. Cohort A6m reflects a multi-dose regimen where patients will receive a total of 10 to 15 billion cells.

* 20M, 100M, 500M, 2.5B, 5.0B to 7.5B and 10B to 15B refers to the number of DSG3-CAART cells infused for patients in dosing cohorts A1 to A (M – millions; B – billions).

DesCAARTes[™] clinical trial assessments & current timeframes

Safety assessed acutely, at 28 days & at 3 months, with data on biologic activity within 6 months



Cabaletta Bio

13


* Clearance of 28-day observation window without DLTs required to initiate next dosing cohort. DLTs include any grade 3 or 4 CRS or neurotoxicity, or any Grade 2 CRS or neurotoxicity that failed to improve to \leq Grade 1 or baseline within 7 days

1. This information represents data that we believe can be used to inform potential efficacy endpoints in future clinical development.

2. Spindler, Volker, et al. "Mechanisms causing loss of keratinocyte cohesion in pemphigus." Journal of Investigative Dermatology 138.1 (2018): 32-37.

No DLTs observed to date in first 4 cohorts of DesCAARTes™ trial

Favorable safety profile at all reported doses of DSG3-CAART, including the 2.5B cell dose cohort




Cohort A5 (two-split fractionated dose of 5.0-7.5B cells) progressing; additional clinical data for cohort A4 expected to be provided at a scientific meeting in mid-2022

* 20M, 100M, 500M, 2.5B, 5.0B to 7.5B and 10B to 15B refers to the number of DSG3-CAART cells infused for patients in dosing cohorts A1 to A6m (M – millions; B – billions).

14

Dose-dependent persistence of DSG3-CAART in cohorts A1 to A4

DSG3-CAART persistence in cohort A4 approached levels seen in CART-19 with lymphodepletion in oncology



Ongoing & planned cohorts designed to further increase DSG3-CAART exposure


Cabaletta Bio

15

- 1. Mueller, Karen Thudium, et al. "Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia." Blood, The Journal of the American Society of Hematology 130.21 (2017): 2317-2325.
- 2. Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019;380(1):45-56. doi:10.1056/NEJMoa1804980
- 3. The range of persistence observed with anti-CD19 CART therapy in oncology has not been confirmed to be necessary or sufficient for clinical responses in patients with mPV.
- * A1-1-R refers to a subject in cohort A1 who was retreated at the cohort A3 dose (500 million cells).

Optimizing DSG3-CAART product and patient profiles

Range of strategies to consider for targeted cell therapy approaches in patients with autoimmune diseases



Many options exist to optimize product and patient profiles, ongoing evaluation of strategies to enhance DSG3-CAART exposure

Pathogenic autoreactive B cell


Healthy B cell

AART cell

MuSK-CAART for patients with MuSK myasthenia gravis

High unmet need in MuSK myasthenia gravis; a valuable CAAR target

All known extracellular domains can be included in the CAAR design



Cabaletta Bio


1. Hain, Berit, et al. "Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab." Muscle & Nerve: Official Journal of the American Association of Electrodiagnostic Medicine 33.4 (2006): 575-580.

2. Illa, Isabel, et al. "Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients." Journal of neuroimmunology 201 (2008): 90-94.

3. Jiang, Ruoyi, et al. "Single-cell repertoire tracing identifies rituximab-resistant B cells during myasthenia gravis relapses." JCI insight 5.14 (2020).

MuSK-CAART demonstrated specific in vivo target engagement¹

MuSK-CAART eliminated anti-MuSK target cells² in an animal model where CART19 cells were a positive control



MuSK-CAART IND open and planning to initiate first-in-human MuSK-CAART trial in 2022

1. https://cabalettabio.com/technology/posters-publications; recently presented at AAI Immunology 2022, MGFA International and ASGCT 2022 conferences in May 2022.


2. Target cells represent a B cell tumor line (CD19 positive) that has been modified to express the anti-MuSK antibody.



MusCAARTes[™] study of MuSK-CAART

Strategy for upcoming trial evaluating MuSK-CAART informed by progression of DesCAARTes™ study

Open-label study to determine the maximum tolerated dose & to evaluate safety of MuSK-CAART



Study Endpoint & Objectives

Primary Endpoint: Adverse Events, including DLT

Secondary & Tertiary Objectives: CAAR T expansion/persistence, effect on serum anti-MuSK antibody titer, use of concomitant systemic medications, effect on clinical symptoms, manufacturing success rate

* 100M, 500M, 2.5B and 5.0B to 7.5B refers to the number of MuSK-CAART cells infused for patients in dosing cohorts A1 to A4 (M – millions; B – billions). 1. A total of 6 subjects will need to have received the final selected dose in Part A of the study. Cabaletta Bio®

20

Fast Track Designation


PLA2R-CAART for patients with PLA2R-associated membranous nephropathy

Preclinical stage CAART program in membranous nephropathy

Primary MN is an immune-mediated kidney disease with anti-PLA2R antibodies in ~75% of patients

Accumulating evidence of a correlation between PLA2R antibodies and disease activity, remission and relapse in primary MN

- PLA2R autoantibody levels routinely used as diagnostic and prognostic markers
- 2 Autoantibody titer shown to rise rapidly before clinical manifestations
- 3
- Co-localization of antigen & PLA2R antibodies at site of damage in kidney



PLA2R+ MN is attractive for CAAR development

- Epitopes are well-defined
- IgG4-dominant disease, similar to PV and MuSK MG
- Eligible US population
 - prevalence of ~4,000-8,000;
 - incidence of ~700-1,400 / yr

PLA2R-CAART showed *in vitro* antigen-specific cytotoxicity¹

- PLA2R CAARs demonstrated activity in the presence of physiologic levels of anti-PLA2R autoantibodies
- Candidate CAAR contains targets that bind >95% of anti-PLA2R autoantibodies
- Demonstrated no off-target binding interactions in membrane protein array

Manufacturing

Manufacturing strategy

Three-stage approach allows for efficient allocation of capital while leveraging experienced partners

Stage 1: Penn ¹	Stage 2: CDMOs & CABA Process	Stage 3: Cabaletta Facility Commercialization & Scale-Up	
2019 –	2021 –	Data-gated, staged investment	
Children's Hospital of Philadelphia	OxfordBioMedica	Cabaletta Bio®	
 Cell processing capacity secured through Penn partnership SOPs previously used to develop an FDA approved product Clinical vector validated 	 CDMOs for vector and cell processing with commercial support capabilities 	 Leasing followed by engineering and build out of Cabaletta-owned manufacturing facility 	



Corporate Summary

Cabaletta Bio leadership

LEADERSHIP TEAM



Steven Nichtberger, M.D. President, CEO & Chairman

MERCK tengion A Penn





Chief Scientific Officer

Magazimmune





Heather Harte-Hall Chief Compliance Officer Maptimmune Pfizer



Gwendolyn Binder, Ph.D. President, Science & Technology

A Penn

X Adaptimmune



David J. Chang, M.D., M.P.H. Chief Medical Officer

AstraZeneca

🛱 Penn



Anup Marda Chief Financial Officer

Bristol-Myers Squibb

Aimee Payne, M.D., Ph.D.

Co-Founder and Co-Chair

Brian Daniels, M.D.

Carl June, M.D.





Arun Das, M.D. Chief Business Officer

> Goldman Sachs ଭ

Children's Hospital of Philadelphia

Martha O'Connor Chief HR Officer

Bristol-Myers Squibb accentureconsulting

SCIENTIFIC ADVISORY BOARD

Michael C. Milone, M.D., Ph.D. Co-Founder and Co-Chair

Jay Siegel, M.D.

Drew Weissman, M.D., Ph.D.



BOARD OF DIRECTORS

SANDOZ A Novartis

Steven Nichtberger, M.D.

Spark!

Catherine Bollard, M.D.

Mark Simon, M.B.A.

Richard Henriques, M.B.A.

Scott Brun, M.D.

lain McInnes, Ph.D., FRCP, FRSE, FMedSci

Multiple potential data catalysts with possible pipeline read-through

DesCAARTes[™] trial ongoing: Currently progressing cohort A5 (5.0-7.5B cells)

- Data presented at ASGCT 2022 demonstrate dose-dependent increase in persistence
 - Cohort A4 persistence approached the lower end of the range seen in anti-CD19 CART with LD in oncology^{1,2,3}
 - Demonstrated a favorable safety profile in cohorts A1 to A4
- Additional data from the DesCAARTes trial anticipated at scientific meetings in mid-2022
 - Clinical and translational data for cohort A4⁴
 - 28-day safety data for cohort A5⁴
- Multiple additional planned cohorts designed to enhance DSG3-CAART exposure

MuSK-CAART: Plan to initiate first-in-human trial in 2022; received FDA Fast Track Designation



1. Mueller, Karen Thudium, et al. "Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia." Blood, The Journal of the American Society of Hematology 130.21 (2017): 2317-2325.

2. Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019;380(1):45-56. doi:10.1056/NEJMoa1804980

3. The range of persistence observed with anti-CD19 CART therapy in oncology has not been confirmed to be necessary or sufficient for clinical responses in patients with mPV.

4. Assumes no dose-limiting toxicities are observed during each cohort, uninterrupted enrollment and no delays due to COVID-19 resurgence occur in the trial.

* 20M, 100M, 500M, 2.5B, 5.0B to 7.5B and 10B to 15B refers to the number of DSG3-CAART cells infused for patients in dosing cohorts A1 to A6m (M – millions; B – billions).



Cabaletta Bio®

Corporate Presentation

MAY 2022

© 2022 Cabaletta Bio. All rights reserved.